Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCR-MYC
- Development stage
- Discontinued
- Lead developer
- Novo Nordisk
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
DCR-MYC is a lipid nanoparticle-based formulation containing small-interfering RNAs (siRNAs) specifically designed to target and silence the oncogene MYC, which is implicated in the growth of many solid and hematologic malignancies. The drug utilizes RNA interference (RNAi) technology to inhibit expression of c-Myc, a transcription factor that drives cancer cell proliferation and survival. Delivered via a proprietary lipid nanoparticle system (EnCore LNP), this synthetic double-stranded RNA acts as a potent and specific inhibitor of MYC by promoting degradation of its mRNA, thereby reducing protein levels within tumor cells. Developed by Dicerna Pharmaceuticals, later acquired by Novo Nordisk, DCR-MYC was the first MYC-targeting siRNA to enter clinical trials for advanced solid tumors, multiple myeloma, lymphoma, hepatocellular carcinoma (HCC), liver cancer, pancreatic cancer, and non-Hodgkin's lymphoma. Despite initial promise in early-phase studies for these indications, development was discontinued after phase I/II trials[1][2][3][4][5][7].
- Other names
- MYC-targeting siRNA DCR-MYC
02
Targets
MYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on DCR-MYC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCR-MYC.